Global NewsNews

Glenmark receives marketing approval for Ryaltris in 13 countries

Raltris will be marketed in the rest of Europe by the Menarini Group as part of its exclusive licensing agreement with Glenmark

Glenmark Pharmaceuticals has received marketing approval for its fixed-dose combination nasal spray Ryaltris in 13 countries across the EU and the UK. Glenmark is set to launch Ryaltris directly in the markets of the Czech Republic, Slovakia, Poland, and the UK. Ryaltris will be marketed in the rest of Europe by the Menarini Group as part of its exclusive licensing agreement with Glenmark.

Ryaltris (olopatadine 665 μg and mometasone furoate 25 μg), is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age. Ryaltris relieves
symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.

Robert Crockart, Chief Commercial Officer, Glenmark Pharmaceuticals, said, “Allergic rhinitis is both widespread and underreported, making it challenging to diagnose and treat in time. It impacts a person’s quality of life and can lead to functional impairments, while also increasing the risk of asthma. This marketing approval will pave the way for the effective and timely treatment of allergic rhinitis for thousands of patients across Europe. We are already seeing its therapeutic benefits in other regions where Ryaltris has been launched, and we hope to extend this relief to more people across the world.”

Glenmark has also partnered with Hikma Pharmaceuticals and Bausch Health for the commercialisation of Ryaltris in the US and Canada respectively. In April this year, Glenmark concluded the DCP regulatory
procedure in Europe, enabling approval in 17 countries across the EU and the UK.

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
IndiaMedToday
Close
Close